PAP
CAPR icon

Persistent Asset Partners’s Capricor Therapeutics CAPR Stock Holding History

Persistent Asset Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$999K Hold
831
– – 0.37% 63
2025
Q4 		$964K Buy
831
+142
+21% +$1.85K 0.43% 65
2025
Q3 		$72.6K Buy
+689
New +$5.07K 0.05% 167
2025
Q2 		– Sell
-70
Closed -$525 – 188
2025
Q1 		$525 Sell
70
-535
-88% -$7.43K ﹤0.01% 170
2024
Q4 		$115K Buy
+605
New +$10.6K 0.1% 99

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Persistent Asset Partners's CAPR Position: Q1 2026 in Review

Persistent Asset Partners reduced its Capricor Therapeutics (CAPR) stake by 61% in Q1 2026, selling an estimated $841K and leaving 19,933 shares worth $606K. The position accounts for 0.23% of the portfolio, ranked #96.

Persistent Asset Partners first reported a position in CAPR in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.49M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Persistent Asset Partners held 19,933 shares of Capricor Therapeutics worth $606K as of Q1 2026.
  • Persistent Asset Partners sold 31,548 Capricor Therapeutics shares in Q1 2026, an estimated $841K.
  • Capricor Therapeutics made up 0.23% of Persistent Asset Partners's portfolio in Q1 2026, its #96 holding.
  • Persistent Asset Partners first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Capricor Therapeutics position peaked at $1.49M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.